Interim Results

Summary by AI BETAClose X

hVIVO plc reported interim results for the six months ended 30 June 2026, with revenue of £16.3 million, down from £24.2 million in the prior year, and an adjusted EBITDA loss of £4.5 million, an increase from a £3.0 million loss in H1 2025. Despite this, the contracted orderbook more than doubled to £65 million, and cash stood at £13.0 million. The company acquired CRS Berlin, expanding its clinical platform, and anticipates H2 2026 revenue to be approximately double that of H1, with full-year 2026 revenue projected at £47 million. Positive adjusted EBITDA is expected in H2 2026, with a low single-digit adjusted EBITDA loss for the full year.

Disclaimer*

Companies

Hvivo (HVO)
UK 100

Latest directors dealings